Hidradenitis Suppurativa

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from povorcitinib treatment, Incyte announced in a press release.

Glucagon-like peptide-1 receptor agonists, an increasingly popular class of weight loss medications, have been found to be associated with new onset acne in women, according to a research letter published in Journal of the American Academy of Dermatology.

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.

New data showed that Bimzelx sustained disease control of hidradenitis suppurativa up to 2 years, UCB announced in a press release.

MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.

Fair representation of patients with skin of color in melasma trials has signaled a trend toward inclusivity in dermatology, setting a precedent for other indications, according to a study.

The single-injection 2 mL prefilled syringe and autoinjector for Bimzelx 320 mg is now available, UCB announced in a press release.

The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.

The FDA has cleared the investigational new drug application for STAR-0310 as a potential treatment for atopic dermatitis and other diseases, Astria Therapeutics announced in a press release.

As the year comes to a close, Healio Dermatology has assembled this year’s top hidradenitis suppurativa articles.